Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Peripheral Neuropathy

Trial Information

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity

The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.
• Male or non-fertile females
• Painful symptoms due to neuropathic pain for a period of 3 months to 5 years, associated with mechanical allodynia and/or punctate hyperalgesia.

Exclusion Criteria:

• Other pain that may confound assessment of neuropathic pain.
• Diagnosis of any severe neurological disease.
• History of significant psychiatric disease/condition and/or history of psychotic disorders among first degree relatives.

Tracy Critchfield, MSM, Marketing/Recruitment Specialist
Clinical Trials of Texas, Inc.
7940 Floyd Curl Dr., Suite 700
San Antonio, TX 78229
Phone: 210.949.0122
Fax: 210.949.0181

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.